Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 186-192

  Tarabar, Olivera ^a   Cikota Aleksić, Bojana ^a   Tukić, Ljiljana ^a   Milanović, Nenad ^b   Aleksić, Aleksandar ^a   Magić, Zvonko ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Diffuse large B cell lymphoma; Gene polymorphism; Interleukin 10; Transforming growth factor ; Tumor necrosis factor

Indexed keywords

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 84894546526     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0531-z     Document Type: Article

References (50)

1. Gatter KC, Warnke RA (2001) Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 171-174
2. Coiffier B, Thieblemont C, Van Den Neste E, et al. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de I'Adulte. Blood 116:2040-2045
3. Habermann TM, Weller EA, Morrison VA, et al. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127
4. Pfreundschuh M, Trumper L, Osterborg A, et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
5. + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116
6. Chatterjee N, Hartge P, Cerhan JR, et al. (2004) Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 13:1415-1421
7. Alexander DD, Mink PJ, Adami HO, et al. (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12):1-39
8. Keen LJ (2002) The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol 10:143-146
9. Wilson AG, Symons JA, McDowell TL, et al. (1997) Effects of a polymorphism in human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199
10. Escdale J, Gallagher G, Verweij C, et al. (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95:9465-9470
11. Bidwell J, Keen L, Gallagher G, et al. (2001) Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2:61-70
12. Czarneski J, Lin YC, Chong S, et al. (2004) Studies in IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 18:597-606
13. Korner H, Cretney E, Wilhelm P, et al. (2000) Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med 191:89-96
14. Karin M, Greten FR (2005) NF-kB: linking inflammation and immunity to cancer development and prognosis. Nat Rev Immunol 5:749-759
15. Douglas RS, Capocasale RJ, Lamb RJ, et al. (1997) Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 89:941-947
16. Moore KW, deWaal Malefyt R, Coffman RL, et al. (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19(68):3-765
17. Pasparakis M, Alexopulou L, Episkopou V, et al. (1996) Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in formation of primary B cell follicles, follicular dendritic networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397-1411
18. Ruscetti FW, Akel S, Bartelmez SH (2005) Autocrine transforming growth factor-β regulation of hematopoiesis: many outcomes that depend on the context. Oncogene 24:5751-5763
19. Alas S, Emmanouilides Ch, Bonavida B (2001) Inhibition of interleukin-10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723
20. Rothman N, Skibola CF, Wang SS, et al. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the Inter-Lymph Consortium. Lancet Oncol 7:27-38
21. Purdue MP, Lan Q, Kricker A, et al. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 28:704-712
22. Lan Q, Zheng T, Rothman N, et al. (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101-4108
23. Wang S, Cerhan J, Hartge P, et al. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66:9771-9780
24. Spink CF, Keen LJ, Mensah FK, et al. (2006) Association between non-Hodgkin lymphoma and haplotypes in the TNF region. BJ Haematol 133:293-300
25. Lech-Maranda E, Baseggio L, Bienvenu J, et al. (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103:3529-3534
26. Warzocha K, Ribeiro P, Bienvenu J, et al. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:357-381
27. Kube D, Hua TD, von Bonin F, et al. (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 14:3777-3784
28. Shipp MA, Harrington DP, Anderson JR, et al. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
29. Cheson BD, Horning SJ, Coiffier B, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244-1253
30. Tang GJ, Huang SL, Yien HW, et al. (2000) Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 28:2733-2736
31. Sambrook J, Fritsch EF, Maniatis T (1989) Preparation of organic reagents. In: Nolan C (ed) Molecular cloning, a laboratory manual. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, pp B4-B5
32. Perrey C, Turner SJ, Pravica V, et al. (1999) ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β, and TGF-β1 gene polymorphisms. Transpl Immunol 7:127-128
33. Habermann TM, Wang SS, Maurer MJ, et al. (2008) Host immune gene polymorphisms in combination with clinical and demographic factors predicts late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112:2694-2702
34. Kobayashi D, Watanabe N, Yamauchi N, et al. (1997) Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients. Blood 89:2472-2479
35. Jazirehi AR, Huerta-Yepez S, Cheng G, et al. (2005) Rituximab (chimeric anti CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitisation to chemotherapeutic drug-induced apoptosis. Cancer Res 65:264-276
36. Mira J-P, Cariou A, Grall F, et al. (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282:561-568
37. Blay J-Y, Burdin N, Rousset F, et al. (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82:2169-2174
38. Gibson AW, Edberg JC, Wu J, et al. (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-1-production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915-3922
39. Kube D, Hua TD, Kloss M, et al. (2007) The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 8:164-167
40. Berglund M, Thunberg U, Roos G, et al. (2005) The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105:4894-4895 (author reply 5)
41. Cambien F, Ricard S, Troesch A, et al. (1996) Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure: the Etude cas-Temoin de L'infarctus du Myocarde (ECTIM) Study. Hypertension 28:881-887
42. Dunning AM, Ellis PD, McBride S, et al. (2003) A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610-2615
43. Crilly A, Hamilton J, Clark CJ, et al. (2002) Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61:678-681
44. Arkwright PD, Laurie S, Super M, et al. (2000) TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55:459-462
45. Yokota M, Ichihara S, Lin TL, et al. (2000) Association of a T29>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783-2787
46. Mazur G, Bogunia-Kubik K, Wrobel T, et al. (2006) TGF-β1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 33:145-149
47. Padyukov L, Lampa J, Heimburger M, et al. (2003) Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62:526-529
48. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36-45
49. Ivanov V, Tabouret E, Chuto G, et al. (2010) Rituximab-lenalidomide- dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51:1758-1760
50. 2 CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 25:1877-1881